Thematic Institutional Excellence Programme(TKP2021-EGA-24) Támogató: Emberi Erőforrások
Minisztériuma
(739593) Támogató: Horizon 2020
Hungarian Brain Research Program(2017-1.2.1-NKP-2017-00002) Támogató: NKFIH
(STIA-18-KF)
(STIA_21_KF)
Central nervous system (CNS) lymphoma is a rare and aggressive non-Hodgkin lymphoma
that might arise in the CNS (primary CNS lymphoma, PCNSL) or disseminates from a systemic
lymphoma to the CNS (secondary CNS lymphoma, SCNSL). Dysregulated expression of microRNAs
(miRNAs) is associated with various pathological processes and miRNA expression patterns
may have diagnostic, prognostic and therapeutic implications. However, miRNA expression
is understudied in CNS lymphomas. We performed expression analysis of 798 miRNAs in
73 CNS lymphoma samples using the NanoString platform, followed by an analysis to
identify potential diagnostic biomarkers characterizing subgroups and to examine differences
based on their primary and secondary nature, molecular subtype, mutational patterns
and survival. We identified 31 differentially expressed miRNAs between primary and
secondary groups. Additionally, we identified 7 more miRNAs associated with a molecular
subtype and 25 associated with mutation status. Using unsupervised clustering methods,
we defined a small but distinct primary CNS lymphoma subgroup, with characteristically
different expression patterns compared to the rest of the cases. Finally, we identified
differentially regulated pathways in the above comparisons and assessed the utility
of miRNA expression patterns in predicting survival. Our study identifies a novel
CNS lymphoma subgroup defined by distinct miRNAs, proves the importance of specific
miRNAs and pathways in their pathogenesis, and provides the basis for future research
in defining potential biomarkers.